Squarepoint’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $166M | Buy |
315,164
+214,855
| +214% | +$121M | 0.18% | 92 |
|
|
2026
Q1 | $56.4M | Buy |
100,309
+42,885
| +75% | +$27.5M | 0.07% | 301 |
|
|
2025
Q4 | $38.8M | Buy |
57,424
+55,290
| +2,591% | +$37.7M | 0.04% | 499 |
|
|
2025
Q3 | $1.36M | Sell |
2,134
-170,467
| -99% | -$103M | ﹤0.01% | 2413 |
|
|
2025
Q2 | $92.6M | Buy |
172,601
+131,001
| +315% | +$62.6M | 0.1% | 227 |
|
|
2025
Q1 | $17.5M | Sell |
41,600
-121,910
| -75% | -$52.9M | 0.02% | 752 |
|
|
2024
Q4 | $67.6M | Buy |
163,510
+85,214
| +109% | +$37.4M | 0.07% | 288 |
|
|
2024
Q3 | $39.6M | Sell |
78,296
-39,018
| -33% | -$19M | 0.06% | 316 |
|
|
2024
Q2 | $57.2M | Buy |
117,314
+31,287
| +36% | +$15.7M | 0.09% | 203 |
|
|
2024
Q1 | $46.4M | Buy |
86,027
+50,229
| +140% | +$27.4M | 0.08% | 284 |
|
|
2023
Q4 | $19.9M | Sell |
35,798
-120,704
| -77% | -$56.7M | 0.04% | 579 |
|
|
2023
Q3 | $68.4M | Buy |
156,502
+58,559
| +60% | +$29.2M | 0.17% | 106 |
|
|
2023
Q2 | $49.2M | Buy |
97,943
+88,257
| +911% | +$42.3M | 0.15% | 135 |
|
|
2023
Q1 | $4.84M | Sell |
9,686
-341
| -3% | -$163K | 0.02% | 899 |
|
|
2022
Q4 | $4.09M | Sell |
10,027
-8,085
| -45% | -$3.14M | 0.02% | 941 |
|
|
2022
Q3 | $5.9M | Buy |
18,112
+14,828
| +452% | +$5.45M | 0.03% | 661 |
|
|
2022
Q2 | $1.15M | Buy |
+3,284
| New | +$1.34M | 0.01% | 1518 |
|
|
2022
Q1 | – | Sell |
-22,594
| Closed | -$14.9M | – | 3158 |
|
|
2021
Q4 | $14.9M | Sell |
22,594
-15,477
| -41% | -$9.72M | 0.04% | 394 |
|
|
2021
Q3 | $23.7M | Buy |
38,071
+36,836
| +2,983% | +$24.8M | 0.07% | 265 |
|
|
2021
Q2 | $780K | Sell |
1,235
-15,171
| -92% | -$8.38M | ﹤0.01% | 1818 |
|
|
2021
Q1 | $8.03M | Buy |
16,406
+14,171
| +634% | +$7.1M | 0.05% | 440 |
|
|
2020
Q4 | $1.12M | Sell |
2,235
-47,395
| -95% | -$21.2M | 0.01% | 1259 |
|
|
2020
Q3 | $19.5M | Buy |
49,630
+37,048
| +294% | +$13.7M | 0.26% | 82 |
|
|
2020
Q2 | $4.15M | Buy |
+12,582
| New | +$3.64M | 0.07% | 393 |
|
|
2019
Q3 | – | Sell |
-16,000
| Closed | -$4.41M | – | 2487 |
|
|
2019
Q2 | $4.41M | Sell |
16,000
-3,500
| -18% | -$862K | 0.04% | 477 |
|
|
2019
Q1 | $4.36M | Sell |
19,500
-64,380
| -77% | -$13.3M | 0.05% | 486 |
|
|
2018
Q4 | $15.6M | Buy |
83,880
+77,034
| +1,125% | +$15.8M | 0.18% | 127 |
|
|
2018
Q3 | $1.71M | Sell |
6,846
-1,928
| -22% | -$468K | 0.02% | 780 |
|
|
2018
Q2 | $1.91M | Buy |
+8,774
| New | +$1.81M | 0.03% | 645 |
|
|
2017
Q4 | – | Sell |
-9,344
| Closed | -$1.45M | – | 2196 |
|
|
2017
Q3 | $1.45M | Sell |
9,344
-12,261
| -57% | -$1.94M | 0.03% | 602 |
|
|
2017
Q2 | $3.49M | Buy |
21,605
+13,949
| +182% | +$2.27M | 0.07% | 348 |
|
|
2017
Q1 | $1.18M | Buy |
+7,656
| New | +$1.06M | 0.03% | 547 |
|
|
2016
Q3 | – | Sell |
-2,389
| Closed | -$222K | – | 1117 |
|
|
2016
Q2 | $222K | Sell |
2,389
-1,399
| -37% | -$120K | 0.01% | 856 |
|
|
2016
Q1 | $297K | Buy |
+3,788
| New | +$273K | 0.02% | 832 |
|
|
2015
Q2 | – | Sell |
-5,502
| Closed | -$425K | – | 531 |
|
|
2015
Q1 | $425K | Buy |
+5,502
| New | +$428K | 0.15% | 221 |
|
Other funds holding IDXX
Squarepoint's IDXX Position: Q2 2026 in Review
Squarepoint increased its Idexx Laboratories (IDXX) stake by 214% in Q2 2026, buying an estimated $121M and bringing the position to 315,164 shares worth $166M. The position accounts for 0.18% of the portfolio, ranked #92.
Squarepoint first reported a position in IDXX in Q1 2015 and has held it in 35 quarters since. 1,296 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.
- Squarepoint held 315,164 shares of Idexx Laboratories worth $166M as of Q2 2026.
- Squarepoint bought 214,855 Idexx Laboratories shares in Q2 2026, an estimated $121M.
- Idexx Laboratories made up 0.18% of Squarepoint's portfolio in Q2 2026, its #92 holding.
- Squarepoint first reported a position in Idexx Laboratories in Q1 2015 and has held it in 35 quarters since.
- 1,296 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.